A Factorial Randomized Clinical Trial of Nicotine Replacement Therapy and Treatment Recommendations to Quit Versus Continue E-cigarettes When Quitting Smoking in Young Adult Dual Users.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

Little is known regarding nicotine replacement therapy (NRT) for young adult dual users, or whether to recommend quitting versus continuing e-cigarettes during smoking cessation treatment.

Who Took Part

PubMed indexes the participants as teenagers, young adults and adults, both men and women.

This 2 × 2 factorial trial randomized 396 young adult dual users (aged 18-29; ≥ 5 cigarettes/day; used e-cigarettes on ≥ 10 of past 30 days) to receive 12 weeks of combination NRT versus No NRT to quit smoking, plus text-based treatment recommendations to Quit versus Continue E-cigarettes.

The primary outcome was self-reported end-of-treatment 7-day point-prevalence abstinence (PPA) from cigarettes; a secondary outcome was end-of-treatment 30-day PPA from cigarettes.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

PubMed files the paper under topics including Smoking Cessation, Electronic Nicotine Delivery Systems, Tobacco Use Cessation Devices and Nicotine Replacement Therapy.

What This Means in Plain Language

The paper is a randomized study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.